Erik H Van Iterson1, Courtney M Wheatley2, Sarah E Baker3, Wayne J Morgan4, Eric M Snyder5. 1. Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; School of Kinesiology, University of Minnesota, Cooke Hall, 1900 University Ave. SE. Minneapolis, MN 55455, USA. Electronic address: vaniterson.erik@mayo.edu. 2. Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; College of Pharmacy, University of Arizona, 1295 N Martin Ave., Tucson, AZ 85721, USA. 3. College of Pharmacy, University of Arizona, 1295 N Martin Ave., Tucson, AZ 85721, USA; Department of Anesthesiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 4. Department of Pediatrics, University of Arizona, 1501 N. Campbell Ave., Room 3301, Tucson, AZ 85724, USA. 5. School of Kinesiology, University of Minnesota, Cooke Hall, 1900 University Ave. SE. Minneapolis, MN 55455, USA; College of Pharmacy, University of Arizona, 1295 N Martin Ave., Tucson, AZ 85721, USA.
Abstract
BACKGROUND: Individuals with cystic fibrosis (CF) have reduced pulmonary function and exercise tolerance. Additionally, these individuals may develop abnormal cardiac function. The implications of abnormal cardiac function on exercise tolerance are unclear in CF. OBJECTIVE: Study relationships between exercise cardiac hemodynamics and exercise tolerance in CF. METHODS: 17 CF and 25 controls participated in cardiopulmonary exercise testing to measure exercise duration and peak workload (PW). Cardiac index (QI) was measured using acetylene rebreathe and oxygen uptake (VO2) breath-by-breath. Forced expiratory volume in 1-second (FEV1) was performed at rest. RESULTS: Peak QI was 6.7 ± 0.5 vs. 9.1 ± 0.3 mL/min/m(2), CF vs. controls, respectively (P < 0.05). Linear regressions between QI (R(2) = 0.63 and 0.51) and exercise duration or PW were stronger than VO2 (R(2) = 0.35 and 0.37) or FEV1 (R(2) = 0.34 and 0.36) in CF, respectively (P < 0.05). CONCLUSION: These data are clinically relevant suggesting attenuated cardiac function in addition to low airway function relate to exercise tolerance in CF.
BACKGROUND: Individuals with cystic fibrosis (CF) have reduced pulmonary function and exercise tolerance. Additionally, these individuals may develop abnormal cardiac function. The implications of abnormal cardiac function on exercise tolerance are unclear in CF. OBJECTIVE: Study relationships between exercise cardiac hemodynamics and exercise tolerance in CF. METHODS: 17 CF and 25 controls participated in cardiopulmonary exercise testing to measure exercise duration and peak workload (PW). Cardiac index (QI) was measured using acetylene rebreathe and oxygen uptake (VO2) breath-by-breath. Forced expiratory volume in 1-second (FEV1) was performed at rest. RESULTS: Peak QI was 6.7 ± 0.5 vs. 9.1 ± 0.3 mL/min/m(2), CF vs. controls, respectively (P < 0.05). Linear regressions between QI (R(2) = 0.63 and 0.51) and exercise duration or PW were stronger than VO2 (R(2) = 0.35 and 0.37) or FEV1 (R(2) = 0.34 and 0.36) in CF, respectively (P < 0.05). CONCLUSION: These data are clinically relevant suggesting attenuated cardiac function in addition to low airway function relate to exercise tolerance in CF.
Authors: M Sinaasappel; M Stern; J Littlewood; S Wolfe; G Steinkamp; Harry G M Heijerman; E Robberecht; G Döring Journal: J Cyst Fibros Date: 2002-06 Impact factor: 5.482
Authors: A A Ionescu; A A Ionescu; N Payne; I Obieta-Fresnedo; A G Fraser; D J Shale Journal: Am J Respir Crit Care Med Date: 2001-04 Impact factor: 21.405
Authors: Thomas F Solbach; Barbara Paulus; Michael Weyand; Thomas Eschenhagen; Oliver Zolk; Martin F Fromm Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-04-08 Impact factor: 3.000
Authors: Erik H Van Iterson; Sarah E Baker; Courtney M Wheatley; Wayne J Morgan; Thomas P Olson; Eric M Snyder Journal: Clin Med Insights Circ Respir Pulm Med Date: 2018-07-25